Drug Profile
Ulevostinag - Merck & Co
Alternative Names: MK-1454Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Merck & Co; Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Nucleotides
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours; Squamous cell cancer
Most Recent Events
- 30 Sep 2022 Merck Sharp & Dohme completes a phase II trial in Squamous cell cancer (Combination therapy, First-line therapy, Inoperable/unresectable, Metastatic disease) in USA, United Kingdom, South Korea, Brazil, Austria, Australia, Norway, Israel, France and Spain (Intratumoural) (NCT04220866)
- 03 May 2022 Discontinued - Phase-I for Lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in Israel, South Korea (Intratumoural) (Merck & Co pipeline, May 2022)
- 03 May 2022 Discontinued - Phase-I for Lymphoma (Late-stage disease, Metastatic disease, Monotherapy) in France, United Kingdom, South Korea, USA (Intratumoural) (Merck & Co pipeline, May 2022)